How are energy investors positioned?
BILLERICA, Mass. - Bruker Corporation (NASDAQ:BRKR) reported fourth-quarter earnings that surpassed analyst expectations, while also providing a 2025 outlook largely in line with Wall Street estimates.
The scientific instruments maker saw its shares rise 1% following the announcement.
For the fourth quarter of 2024, Bruker posted adjusted earnings per share of $0.76, exceeding the analyst consensus of $0.74. Revenue for the period came in at $979.6 million, topping estimates of $962.38 million and representing a 14.6% increase YoY. The company’s organic revenue growth was 3.9%, with its Bruker Scientific Instrument segment growing 4.5% organically.
Bruker’s non-GAAP operating margin for Q4 stood at 18.1%, with the company noting that operational excellence and integration initiatives fully offset strategic M&A and foreign exchange operating margin headwinds.
Looking ahead, Bruker initiated its fiscal year 2025 guidance, projecting revenue between $3.47 billion and $3.54 billion, representing growth of 3% to 5% YoY. The company expects adjusted EPS for 2025 to range from $2.67 to $2.72, suggesting an increase of 11% to 13% YoY.
Frank H. Laukien, Bruker’s President and CEO, commented on the results: "The year 2024 was transformational for Bruker. We completed several strategic acquisitions to access very large addressable markets with strong secular tailwinds. In the process, we added key spatial biology, molecular diagnostics and lab automation platforms to our portfolio."
Bruker’s full-year 2024 revenue reached $3.37 billion, up 13.6% YoY, with organic revenue growth of 4.0%. The company’s performance marks its fourth consecutive year of above-market organic growth and double-digit constant-exchange rate revenue expansion.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.